Trial Profile
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2018
Price :
$35
*
At a glance
- Drugs Crisantaspase (Primary) ; Crisantaspase (Primary) ; Cytarabine (Primary) ; Fludarabine (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; B-cell lymphoma; Burkitt's lymphoma; Chronic myeloid leukaemia; Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 22 Jun 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 Mar 2018 Planned End Date changed from 1 Feb 2021 to 1 May 2022.
- 13 Mar 2018 Planned primary completion date changed from 1 Feb 2021 to 1 May 2021.